According to Deutsche Bank, there are 156 COVID-19 in preclinical stage, 31 in phase I of trials, 15 and 11 in phase II and III respectively, while six have received limited approval.
Having several potential jabs is beneficial since vaccines rarely make it to commercialisation, while different segments of the populations may need diverse formulations.
Experts see a mass immunisation as the most effective way to end the pandemic until an effective treatment for coronavirus is found.
Governments have poured money into research: the EU has raised EUR16bn under the Coronavirus Global Response, the US has struck supply deals for US$10.79bn as part of Operation Warp Speed, the UK allocated GBP131mln to University of Oxford and Imperial College London as well as growing its potential stockpile to 340mln inoculations.
Here we have a look at the most promising candidates.
The Oxford vaccine
The Jenner Institute at Oxford University signed a deal with AstraZeneca PLC (LON:AZN) to produce and distribute its candidate, now at the final stage of trials on 30,000 people across the UK, US, South Africa, England, Russia and Brazil.
Trials were halted in early September after a UK volunteer reported serious side effects; they later resumed in the UK and Brazil but were still on hold in the US.
The FTSE 100-listed firm has sourced capacity for 2bn doses and agreed to distribute 100mln in the UK, 300mln in the EU and 400mln in Latin American countries.
The trial, started in July, is expected to end in December with availability likely at year-end, according to Deutsche Bank. It is under rolling review by the European Medicines Agency.
Pfizer and BioNTech
Pfizer Inc. (NYSE:PFE) teamed up with BioNTech (NASDAQ:BNTX) to develop four candidates, with one of them potentially ready for regulatory scrutiny by October. It is the other only candidate under rolling review by the European Medicines Agency, except the Oxford jab.
The pair could have 100mln dose ready by the end of the year, with the ability to supply 1.3bn doses by the end of next year. Trials are expected to finish in May 2021 but it could be available for emergency use this year.
The mRNA-based vaccine, that is now in phase II/III, showed “promising” safety and immunogenicity profile in the first round of trials and it was reported to provoke mild-to-moderate side effects such as fatigue, headache, chills and muscle pain.
In July, the US government agreed to pay Pfizer and BioNTech US$1.95bn to secure access to 100mln doses of their coronavirus vaccine.
Moderna Inc (NASDAQ:MRNA) stunned the markets in the spring after developing a candidate in only 63 days.
The candidate entered the final stage of trials on 30,000 volunteers in the US in July and expects to complete enrollment in September. While the trial is expected to end in October 2022, the formulation could be rolled out for emergency use by end of this year if it gets positive interim results in November.
The biotech, which has never commercialised a vaccine, has produced enough doses for the trials and remains on track to deliver 500mln and potentially up to 1bn jabs per year, beginning in 2021.
Sanofi and GSK
If data is positive, regulatory approval could be achieved by the first half of 2021.
EU, US and UK signed up for 300mln, 100mln and 60mln doses respectively.
In parallel, the partners are scaling up manufacturing of the antigen (Sanofi) and adjuvant (Glaxo) to produce up to 1bn doses per year overall.
CureVac (NASDAQ:CVAC) is also working on a m-RNA based inoculation, and is targeting large-scale human trials for the last quarter of this year based on the results of the current trials.
The German biotech, which jumped by 300% since IPO earlier this month on the tech-led NASDAQ exchange, is discussing to supply the EU with 225mln doses.
It was subject to a tug of war between the country’s government and Donald Trump, who prompted outrage by attempting to buy the low-cost developer in March.
If it works there is potential for 600-900mln doses to be produced by April, while it could be employed for emergency use in early 2021.
It is using the same technologies adopted for the Ebola jab provided to people in the Democratic Republic of Congo in 2019.
Novavax Inc (NASDAQ:NVAX) enrolled the first volunteer for the Phase II of clinical trials in late August, expanding on Phase I by including older adults 60-84 years of age.
Data are expected in the fourth quarter of 2020.
The biotech has secured US$2bn funding for its COVID-19 vaccine programme.
Beijing has approved 4 candidates at the stage III of trials for limited use.
One is being developed by Sinovac, another by CanSino while Sinopharm has two.
Sinovac and Sinopharm are planning to begin commercial production on or before year-end, with a combined production capacity of 600mln units per year and 1bn units by end 2021.
CanSino is running slightly behind on its commercial production as it began Phase 3 trials only in August.
Sinopharm has started administering its vaccines to residents in Wuhan and Beijing. Residents now can make appointments to get the shot with students who need to travel abroad getting priority.
Meanwhile, President Vladimir Putin boasted the world’s first coronavirus vaccine to be registered on August 11, but its speed has been met with scepticism.
Moscow said it would start rolling out the jab, called Sputnik V, by the end of August.
The University of Melbourne also had an already available jab, being a repurposed formulation for tubercolosis, though trials will end in June 2021.
Human challenge studies
It will quarantine young adults at a facility in north London to assess whether the drug provokes an immune response.
This type of study sees healthy participants are vaccinated then exposed to the virus to get infected.
Usually, volunteers participating in vaccine trials are not asked to catch the virus, especially if there are many cases like in the current pandemic. This is why trials last for months.